Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative Bevacizumab for Recurrent Vitreous Hemorrhage
NCT06559488Completed
- Sponsor
- Universitas Padjadjaran
- Start
- Apr 2018
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, single-blind trial of bevacizumab in Vitreous hemorrhage (VH) and diabetic retinopathy (DR), sponsored by Universitas Padjadjaran. Primary endpoint: Incidence and Severity of Vitreal Hemorrhage Post-Operative at 30 days. Started Apr 2018; status: completed.
02
Drugs
bevacizumab
03
Conditions
Vitreous hemorrhage (VH)diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT06559488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06559488.